查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529662

美國氯胺酮診所市場規模、佔有率、趨勢分析報告：按治療、治療方法和細分市場預測，2024-2030 年

U.S. Ketamine Clinics Market Size, Share, & Trends Analysis Report By Treatment (Depression, Anxiety, PTSD, Others), By Therapy (On-site Therapy, Online Therapy), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國氯胺酮診所市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國氯胺酮診所市場規模預計將達到69億美元，2024年至2030年複合年成長率為10.60%。

據 SAMHSA 稱，到 2022 年，大約 19.86% 的成年人（約 5000 萬人）將患有某種形式的精神疾病，4.91% 的人將患有嚴重的精神疾病。精神疾病的盛行率因州而異，從新澤西州的 16.37% 到猶他州的 26.86%。

此外，COVID-19 大流行對成人心理健康產生了負面影響，導致對創新治療的需求增加。根據凱撒家庭基金會的調查，2021 年 2 月，39.3% 的美國成年人報告有焦慮或憂鬱症症狀，較大流行前水準顯著增加。心理健康問題的增加產生了對有效、快速治療的需求，進一步推動了美國市場的成長。

此外，當地服務提供者與在美國提供氯胺酮治療的領先氯胺酮診所提供者的日益整合預計也將增加市場機會。市場參與企業正在採取各種策略措施來增強他們的能力，提高他們的能力，並擴大他們的服務組合。例如，2023 年 10 月，Nue Life Health 被一家專門從事迷幻醫學的風險工作室收購。此次收購符合工作室推進精神健康領域創新治療的使命，特別是透過使用迷幻療法。

美國氯胺酮診所市場報告亮點

  • 依治療方式分類，憂鬱症細分市場在 2023 年佔據最大市場佔有率。這是由於越來越多的美國成年人患有嚴重的憂鬱症。
  • 從治療方法來看，隨著氯胺酮治療精神疾病在美國獲得接受，導致診所擴張，現場治療領域在 2023 年佔據了最大的市場佔有率。
  • 2024 年 2 月，Avesta Ketamine and Wellness 與退伍軍人事務部 (VA) 建立合作夥伴關係，為馬裡蘭州、貝塞斯達、北維吉尼亞和華盛頓特區的退伍軍人提供免費氯胺酮治療。該計劃預計將幫助患有藥物濫用障礙、慢性疼痛、焦慮、創傷後壓力症候群和抗治療性憂鬱症的退伍軍人。

目錄

第1章調查方法與範圍

第2章執行概述

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 法律規範
  • 商業環境分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章治療業務分析

  • 美國氯胺酮診所市場：治療方法變異分析
  • 美國氯胺酮診所市場：治療方法細分儀表板
  • 2023 年和 2030 年治療方法趨勢和市場佔有率分析
  • 依治療方法
  • 憂鬱症
    • 憂鬱症市場，2018-2030
  • 焦慮
    • 焦慮的市場，2018-2030
  • PTSD
    • 創傷後壓力症候群市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第5章治療業務分析

  • 美國氯胺酮診所市場：治療方法變異分析
  • 美國氯胺酮診所市場：治療方法細分儀表板
  • 2023 年和 2030 年治療方法趨勢和市場佔有率分析
  • 依治療方法
  • 現場治療方法
  • 線上治療方法

第6章 競爭狀況

  • 公司分類
  • 公司市場分析
  • 策略規劃
    • 夥伴關係/協作/聯盟
    • 新服務開始了
    • 併購
    • 其他
  • 公司簡介/上市公司
    • NY Ketamine Infusions
    • Stella MSO LLC dba Field Trip Health
    • Ketamine Clinics Los Angeles
    • Klarity Clinic（Tebra Inc.）
    • Vitalitas Denver Ketamine Infusion Center
    • Mindbloom, Inc.
    • Nue Life Health（NueCo Holdings, PBC）
    • Better U, Inc.
    • Innerwell（KBS, Inc.）
    • Klarisana Health
Product Code: GVR-4-68040-092-1

U.S. Ketamine Clinics Market Growth & Trends:

The U.S. ketamine clinics market size is anticipated to reach USD 6.90 billion by 2030, exhibiting a CAGR of 10.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the increase in mental health awareness, the ongoing opioid crisis, and an increasing number of ketamine clinics across the U.S. According to SAMHSA, in 2022, about 19.86% of adults, which is nearly 50 million people, had some form of mental illness, with 4.91% experiencing severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah.

Moreover, the COVID-19 pandemic had a negative impact on the mental health of adults, leading to an increased demand for innovative treatments. A survey by the Kaiser Family Foundation found that 39.3% of adults in the U.S. reported symptoms of anxiety or depressive disorder in February 2021, a significant increase from pre-pandemic levels. This increase in mental health issues has created the need for effective and rapid treatments, further driving the growth of the market in the U.S.

Moreover, the growing consolidation of local service providers with major ketamine clinic providers to offer ketamine treatments in the U.S. is expected to increase opportunities in the market. Market players are undertaking various strategic initiatives to increase their capabilities, improve competencies, and expand their service portfolios. For instance, in October 2023[, Nue Life Health was acquired by a venture studio specializing in psychedelic healthcare. This acquisition aligned with the studio's mission to advance innovative treatments in the mental wellness space, particularly through the use of psychedelic therapies.

U.S. Ketamine Clinics Market Report Highlights:

  • Based on treatment, the depression segment held the largest market share in 2023. This can be attributed to the growing number of American adults burdened with severe major depression.
  • Based on therapy, the on-site therapy segment dominated the market with the largest market share in 2023 owing to the growing acceptance of ketamine therapy for mental health disorders which has led to an expansion of clinics in the U.S.
  • In February 2024, Avesta Ketamine and Wellness entered into a partnership with Veteran Affairs (VA) to provide free ketamine therapy to veterans across Maryland, Bethesda, Northern Virginia, and Washington DC. This initiative was expected to help veterans with substance abuse disorder, chronic pain, anxiety, PTSD, and treatment-resistant depression.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Volume Price Analysis
  • 1.8. Objectives
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. U.S. Ketamine Clinics Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Growing demand for effective mental health treatments
      • 3.3.1.2. Growing acceptance of ketamine's therapeutic potential
      • 3.3.1.3. Increasing investment and partnerships in ketamine clinics
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Potential side effects and risks associated with ketamine therapy
      • 3.3.2.2. Easy accessibility for alternative treatments
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Treatment Business Analysis

  • 4.1. U.S. Ketamine Clinics Market: Treatment Movement Analysis
  • 4.2. U.S. Ketamine Clinics Market: Treatment Segment Dashboard
  • 4.3. Treatment Movement & Market Share Analysis, 2023 & 2030
  • 4.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Treatment
  • 4.5. Depression
    • 4.5.1. Depression market, 2018 - 2030 (USD Million)
  • 4.6. Anxiety
    • 4.6.1. Anxiety market, 2018 - 2030 (USD Million)
  • 4.7. PTSD
    • 4.7.1. PTSD market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Therapy Business Analysis

  • 5.1. U.S. Ketamine Clinics Market: Therapy Movement Analysis
  • 5.2. U.S. Ketamine Clinics Market: Therapy Segment Dashboard
  • 5.3. Therapy Movement & Market Share Analysis, 2023 & 2030
  • 5.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Therapy
  • 5.5. On-site Therapy
    • 5.5.1. On-site therapy market, 2018 - 2030 (USD Million)
  • 5.6. Online Therapy
    • 5.6.1. Online therapy market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Company Market Position Analysis
  • 6.3. Strategy Mapping
    • 6.3.1. Partnership/Collaboration/Alliance
    • 6.3.2. New Service Launch
    • 6.3.3. Mergers & Acquisitions
    • 6.3.4. Others
  • 6.4. Company Profiles/Listing
    • 6.4.1. NY Ketamine Infusions
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Service benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. Stella MSO LLC dba Field Trip Health
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Service benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Ketamine Clinics Los Angeles
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Service benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Klarity Clinic (Tebra Inc.)
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Service benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Vitalitas Denver Ketamine Infusion Center
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Service benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. Mindbloom, Inc.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Service benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Nue Life Health (NueCo Holdings, P.B.C.)
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Service benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Better U, Inc.
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Service benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. Innerwell (KBS, Inc.)
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Service benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Klarisana Health
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Service benchmarking
      • 6.4.10.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. ketamine clinics market revenue estimates and forecast, by treatment, 2018 - 2030 (USD Million)
  • Table 4. U.S. ketamine clinics market revenue estimates and forecast, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. ketamine clinics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Treatment & therapy segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. ketamine clinics market: Market dynamics
  • Fig. 13 U.S. ketamine clinics market: Porter's analysis
  • Fig. 14 U.S. ketamine clinics market: PESTLE analysis
  • Fig. 15 U.S. ketamine clinics market: Treatment segment dashboard
  • Fig. 16 U.S. ketamine clinics market: Treatment movement share analysis
  • Fig. 17 Depression market, 2018 - 2030 (USD Million)
  • Fig. 18 Anxiety market, 2018 - 2030 (USD Million)
  • Fig. 19 PTSD market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. ketamine clinics market: Therapy segment dashboard
  • Fig. 22 U.S. ketamine clinics market: Therapy movement share analysis
  • Fig. 23 On-site therapy market, 2018 - 2030 (USD Million)
  • Fig. 24 Online therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Company categorization
  • Fig. 26 Company market position analysis
  • Fig. 27 Strategic framework